{"shortAnswer":"Retatrutide is investigational: it is still in clinical trials, and FDA has not approved it for any use. The evidence grade is moderate-human for weight loss and blood sugar in trials of up to 80 weeks. Pharmacies may not make it, and versions sold online are illegal.","url":"https://peptideindex.ai/compound/retatrutide","status":"investigational","statusCheckedAt":"2026-10-24T05:04:04.556Z","statusStale":false,"regulatoryAsOf":"2026-10-23","verified":"2026-10-26T00:00:27.207Z","primarySourceUrl":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","clinicallyReviewed":false,"notice":"Information, not medical advice.","id":"0a5be5b5-a651-4e94-b68c-5a8b9cb938e3","object":"compound","slug":"retatrutide","name":"Retatrutide","attrs":{"name":"Retatrutide","class":"dual-or-triple-agonist","access":[{"type":"clinical-trial","detail":"Retatrutide is only available inside clinical trials. Open trials are listed in the trials block below, with the date the official registry was last checked.","source_url":"https://clinicaltrials.gov/study/NCT07165028"}],"trials":[{"nct":"NCT07467447","url":"https://clinicaltrials.gov/study/NCT07467447","phase":"Phase 2","title":"Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight","status":"recruiting","sponsor":"Hudson Biotech","countries":["China"],"us_states":[]},{"nct":"NCT07165028","url":"https://clinicaltrials.gov/study/NCT07165028","phase":"Phase 3","title":"Withheld under our publishing rules. Read it in the official record.","status":"recruiting","sponsor":"Eli Lilly and Company","countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","China","Czechia","France","Germany","Hong Kong","Hungary","India","Israel","Italy","Japan","Mexico","Netherlands","New Zealand","Norway","Poland","Portugal","Puerto Rico","Romania","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"us_states":["Alabama","Arizona","Arkansas","California","Colorado","Connecticut","Florida","Georgia","Illinois","Indiana","Iowa","Kansas","Kentucky","Louisiana","Maryland","Massachusetts","Michigan","Minnesota","Mississippi","Missouri","Nevada","New Jersey","New Mexico","New York","North Carolina","Ohio","Pennsylvania","Rhode Island","South Carolina","Tennessee","Texas","Utah","Virginia","Washington","West Virginia"]}],"aliases":["LY3437943"],"summary":"An experimental weekly shot that acts on three hormones, GIP, GLP-1 and glucagon. It is in late-stage trials for obesity and diabetes and is not approved.","citations":[{"n":1,"url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","tier":"primary","type":"regulatory","title":"FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026"},{"n":2,"url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-vitality-inc-dba-prime-peptides-695156-12102024","tier":"primary","type":"regulatory","title":"FDA warning letter to an online seller of research-use peptides, 10 December 2024"},{"n":3,"url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genlabmeds-713650-09092025","tier":"primary","type":"regulatory","title":"FDA warning letter on compounded retatrutide, 9 September 2025"},{"n":4,"url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medclub-dr-jenn-712126-09092025","tier":"primary","type":"regulatory","title":"FDA warning letter on compounded retatrutide, 9 September 2025, second business"},{"n":5,"url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026","tier":"primary","type":"regulatory","title":"FDA warning letter to an online seller of research-use retatrutide, 31 March 2026"},{"n":6,"url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026","tier":"primary","type":"regulatory","title":"FDA warning letter to an online seller of research-use peptides, 24 August 2026"},{"n":7,"url":"https://clinicaltrials.gov/api/int/studies?query.intr=retatrutide&filter.overallStatus=RECRUITING,NOT_YET_RECRUITING&limit=50&fields=NCTId,BriefTitle,OfficialTitle,OverallStatus,Phase,LeadSponsorName,Condition,InterventionName,LocationState,LocationCountry,BriefSummary,StartDate,LastUpdatePostDate","tier":"primary","type":"reference","title":"ClinicalTrials.gov: recruiting and not yet recruiting studies of retatrutide"},{"n":8,"url":"https://www.afslaw.com/perspectives/alerts/ruo-ined-five-peptide-vendors-learn-research-use-only-not-legal-strategy","tier":"legal-analysis","type":"legal-analysis","title":"ArentFox Schiff: research-use labels are not a legal strategy, 18 September 2026"},{"n":9,"url":"https://pubmed.ncbi.nlm.nih.gov/37366315/","tier":"peer-reviewed","type":"rct","title":"Phase 2 trial of retatrutide in adults with obesity, 2023"},{"n":10,"url":"https://pubmed.ncbi.nlm.nih.gov/37385280/","tier":"peer-reviewed","type":"rct","title":"Phase 2 trial of retatrutide in adults with type 2 diabetes, 2023"},{"n":11,"url":"https://pubmed.ncbi.nlm.nih.gov/38858523/","tier":"peer-reviewed","type":"rct","title":"Phase 2a trial of retatrutide for fatty liver disease, 2024"},{"n":12,"url":"https://pubmed.ncbi.nlm.nih.gov/42250575/","tier":"peer-reviewed","type":"rct","title":"TRANSCEND-T2D-1: phase 3 trial of retatrutide in type 2 diabetes, 2026"},{"n":13,"url":"https://pubmed.ncbi.nlm.nih.gov/42810372/","tier":"peer-reviewed","type":"rct","title":"TRIUMPH-2: phase 3 trial of retatrutide in obesity with type 2 diabetes, 2026"},{"n":14,"url":"https://pubmed.ncbi.nlm.nih.gov/39817343/","tier":"peer-reviewed","type":"systematic-review","title":"Review of trials of retatrutide for obesity, 2025"},{"n":15,"url":"https://www.cbsnews.com/news/eli-lilly-lawsuits-weight-loss-drug/","tier":"established-news","type":"reference","title":"CBS News: the maker sues sellers of its experimental weight-loss drug, August 2026"},{"n":16,"url":"https://www.cbsnews.com/news/tested-experimental-weight-loss-drug-results/","tier":"established-news","type":"reference","title":"CBS News: lab tests of products sold as retatrutide, October 2026"}],"known_risks":["In trials, the most common problems were nausea, diarrhea, vomiting and constipation. They were more common at higher strengths [^9] [^10].","In a mid-stage trial, heart rate went up more at higher strengths. It peaked at 24 weeks and then came down [^9].","In an 80-week trial, low blood pressure and odd skin feelings, such as tingling or burning, happened more often than on a dummy shot [^13].","In that trial, more people on the two higher strengths stopped the drug for good because of bad reactions or death than on a dummy shot [^13].","One vial sold as retatrutide in a New York corner store held no peptide at all. Lab tests found a filler and live bacteria in it [^16].","FDA warns that shots skip some of the body's defenses. Germs or toxins in an untested product can cause life-threatening illness [^5]."],"short_answer":"Retatrutide is investigational: it is still in clinical trials, and FDA has not approved it for any use. The evidence grade is moderate-human for weight loss and blood sugar in trials of up to 80 weeks. Pharmacies may not make it, and versions sold online are illegal.","evidence_grade":"moderate-human","open_questions":["The longest published trial lasted 80 weeks. Nobody knows what years of use do to the body [^13].","The published trials measured weight, blood sugar and liver fat. None has shown yet whether it prevents heart attacks, strokes or early death [^12] [^13].","The liver fat results come from 98 people in one trial. A much larger liver trial is still running [^11] [^7].","Nobody can tell what is in a product sold online. Two online samples matched a basic lab standard, but that standard is not the drug used in trials [^16].","Nobody knows if FDA will approve it. Its maker plans to ask for approval in early 2027 [^8] [^15]."],"section_routes":"The only legal way to get retatrutide in the US is to join a clinical trial [^1] [^7]. No approved product exists, and no pharmacy may lawfully make it [^1] [^3].\n\nOn 23 October 2026 the official trial registry listed two studies open to new people [^7]. One is a large late-stage study of fatty liver disease with sites in many US states. The other is a smaller study with one site in China [^7]. Each trial has strict rules on who may join.\n\nOpen trials are listed in the trials block below, with the date the official registry was last checked.","regulatory_as_of":"2026-10-23","section_channels":"Retatrutide reaches people outside trials in three main ways, and none of them is legal [^1]. The first is online sellers that label it for research use. FDA sent warning letters to such sellers in December 2024, March 2026 and August 2026 [^2] [^5] [^6]. In 2026, a news team also found it for sale in New York corner stores [^16]. The second is businesses that offer it as a compounded drug. FDA warned two of them in September 2025 [^3] [^4]. The third is online health businesses that sell it after a short form. FDA says it has warned such companies [^1]. A news team ordered it from two such sites, and at least one order arrived with no consultation [^16].\n\nIn each case, nobody checks what is in the vial [^1]. One vial a news team tested held no peptide, a filler and live bacteria [^16]. In court, the maker says these products are more likely to hold contaminants [^15]. It has sued six companies and reported more than 200 others to officials [^8] [^15].","section_evidence":"The evidence grade is moderate-human: trials in people show large weight loss and better blood sugar, but they are short and the maker paid for all of them [^9] [^12] [^13]. A mid-stage trial of 338 adults with obesity ran for 48 weeks. People on the highest strength lost about 24% of their weight. People on a dummy shot lost about 2% [^9]. A mid-stage trial of 281 adults with type 2 diabetes found lower HbA1c, a blood test of average blood sugar over about three months [^10]. In a group of 98 people with fatty liver, liver fat fell by more than 80% on the higher strengths [^11].\n\nTwo late-stage trials have now been published. In 537 adults with type 2 diabetes, HbA1c fell by about 1.7 to 1.9 points over 40 weeks, against 0.8 on a dummy shot. Weight fell by 11% to 15% [^12]. In 1,152 adults with obesity and type 2 diabetes, weight fell by 12% to 19% over 80 weeks, against 5% on a dummy shot [^13]. A 2025 review of four trials found it beat a dummy shot on every measure it pooled [^14].\n\nThese trials tested the maker's own drug. They tell us nothing about products sold online, which may hold something else [^16].","regulatory_status":"investigational","section_what_it_is":"Retatrutide is an experimental drug given as a weekly shot under the skin [^9]. It acts on three hormones that help control blood sugar and body weight: GIP, GLP-1 and glucagon [^10]. That is why researchers call it a triple-hormone agonist [^9]. An agonist is a drug that switches on the same signal as a natural hormone.\n\nIts lab code is LY3437943 [^9]. Online sellers often call it Reta [^16]. One drug company developed it and has paid for every large trial so far [^9] [^12] [^13]. It is not sold in any pharmacy, and FDA has not approved it for any condition [^1].","section_is_it_legal":"Retatrutide is investigational: it is being tested in clinical trials, and FDA has not approved it for any use [^1]. That does not make it legal to sell, and it does not let pharmacies make it. Checked 23 October 2026.\n\nIt is being studied for obesity, type 2 diabetes and a fatty liver disease [^7] [^13]. Online, it is sold for weight loss, often with a label saying it is for research only [^1] [^16].\n\nUnder federal law, pharmacies may not use it to make drugs [^1]. It has no official quality standard and is not part of any approved drug. It is also not on either list of raw ingredients that pharmacies or outsourcing facilities may use [^3]. A research-use label does not change this. When a seller's site shows the product is meant for people, FDA treats it as an unapproved new drug [^2] [^5]. Shipping an unapproved new drug across state lines breaks federal law [^6].\n\nIt is not approved anywhere in the world [^8]. Its maker plans to ask FDA for approval in early 2027 [^8] [^15]. In August 2026, the maker sued six companies that sold versions of it [^15].","unofficial_channels":[{"type":"research-use-seller","what_it_is":"Sold online, and in some corner stores, in vials labeled for research use only or not for human use.","enforcement":[{"date":"2024-12-10","text":"FDA warning letter to an online seller of research-use peptides, including retatrutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-vitality-inc-dba-prime-peptides-695156-12102024"},{"date":"2026-03-31","text":"FDA warning letter to an online seller of research-use retatrutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026"},{"date":"2026-08-24","text":"FDA warning letter to an online seller of research-use peptides, including retatrutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026"}],"legal_position":{"text":"FDA treats these as unapproved new drugs when the seller's site shows they are meant for people, whatever the label says.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-vitality-inc-dba-prime-peptides-695156-12102024"},"documented_risks":[{"text":"A vial sold as retatrutide held no peptide. Lab tests found a filler and 13 colonies of bacteria.","source_url":"https://www.cbsnews.com/news/tested-experimental-weight-loss-drug-results/"},{"text":"FDA warns that injected products skip some of the body's defenses, so toxins or germs in them can cause life-threatening illness.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026"},{"text":"FDA says these products are of unknown quality and may harm health.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"}]},{"type":"compounding-outside-the-rules","what_it_is":"Versions offered as compounded drugs by online businesses and pharmacies, made from raw ingredient bought from distributors.","enforcement":[{"date":"2025-09-09","text":"FDA warning letter to an online business offering compounded retatrutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genlabmeds-713650-09092025"},{"date":"2025-09-09","text":"FDA warning letter to a second online business offering compounded retatrutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medclub-dr-jenn-712126-09092025"}],"legal_position":{"text":"Retatrutide cannot be used in compounding under federal law. It is not part of any approved drug and is on no list of allowed raw ingredients.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},"documented_risks":[{"text":"FDA does not check compounded drugs for safety, quality or whether they work before they are sold.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},{"text":"One business told buyers that compounded retatrutide was the active ingredient in approved weight-loss drugs. FDA said that claim was false.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genlabmeds-713650-09092025"}]},{"type":"telehealth","what_it_is":"Online health businesses that sell it after a short online form, sometimes promising a review by a doctor or nurse.","legal_position":{"text":"FDA has warned telehealth companies for marketing unapproved drugs such as retatrutide, including directly to consumers.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},"documented_risks":[{"text":"A news team ordered it from two such sites. At least one order arrived with no talk with a health worker.","source_url":"https://www.cbsnews.com/news/tested-experimental-weight-loss-drug-results/"}]}]},"provenance":{"name":{"fact_id":"38a94faf-fecb-4cd1-a371-912914f542be","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","source_type":"primary","captured_at":"2026-10-24T04:24:23.450Z","checked_at":"2026-10-24T05:04:04.551Z","confidence":1,"stale":false},"class":{"fact_id":"c4acab42-de51-47f1-8336-42658f8a9070","source_url":"https://pubmed.ncbi.nlm.nih.gov/37366315/","source_type":"peer-reviewed","captured_at":"2026-10-24T04:40:15.749Z","checked_at":"2026-10-24T05:04:04.545Z","confidence":1,"stale":false},"access":{"fact_id":"e34ef2fb-ba98-45cf-bf9b-df7b2fe7b774","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","source_type":"primary","captured_at":"2026-10-24T04:24:23.450Z","checked_at":"2026-10-25T06:28:29.856Z","confidence":1,"stale":false},"trials":{"fact_id":"497d9389-f6bd-4187-b89b-09d5a33a00bf","source_url":"https://clinicaltrials.gov/api/v2/studies?query.intr=retatrutide+OR+LY3437943&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState","source_type":"primary","captured_at":"2026-10-24T13:34:34.504Z","checked_at":"2026-10-24T13:34:34.504Z","confidence":1,"stale":false},"aliases":{"fact_id":"60f578c6-e26e-4c8b-931c-b148b14f7253","source_url":"https://pubmed.ncbi.nlm.nih.gov/37366315/","source_type":"peer-reviewed","captured_at":"2026-10-24T04:40:15.749Z","checked_at":"2026-10-24T05:04:04.541Z","confidence":1,"stale":false},"summary":{"fact_id":"df87d47b-d619-4fac-abdb-8be098cc21d2","source_url":"https://pubmed.ncbi.nlm.nih.gov/42810372/","source_type":"peer-reviewed","captured_at":"2026-10-24T04:40:18.805Z","checked_at":"2026-10-24T05:04:04.570Z","confidence":1,"stale":false},"citations":{"fact_id":"4a2c1815-bec1-4102-a0a0-14f9b143134c","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","source_type":"primary","captured_at":"2026-10-24T04:24:23.450Z","checked_at":"2026-10-24T05:04:04.543Z","confidence":1,"stale":false},"known_risks":{"fact_id":"dbff67ad-c867-4e1a-ba58-67fa2ac1ab81","source_url":"https://pubmed.ncbi.nlm.nih.gov/42810372/","source_type":"peer-reviewed","captured_at":"2026-10-24T04:40:18.805Z","checked_at":"2026-10-24T05:04:04.549Z","confidence":1,"stale":false},"short_answer":{"fact_id":"89e4cdc7-f27c-457b-8033-da550692cfb5","source_url":"https://peptideindex.ai/methodology#short-answer","source_type":"reference","captured_at":"2026-10-24T03:55:12.975Z","checked_at":"2026-10-24T05:04:04.568Z","confidence":1,"stale":false,"label":"our assessment"},"evidence_grade":{"fact_id":"6daa77dc-ccda-4888-974e-35faea419c9a","source_url":"https://peptideindex.ai/methodology#evidence-grade","source_type":"reference","captured_at":"2026-10-24T03:55:13.723Z","checked_at":"2026-10-24T05:04:04.547Z","confidence":1,"stale":false,"label":"our assessment"},"open_questions":{"fact_id":"ee8318e6-2b4f-477e-9eb5-e81219d4460e","source_url":"https://pubmed.ncbi.nlm.nih.gov/42810372/","source_type":"peer-reviewed","captured_at":"2026-10-24T04:40:18.805Z","checked_at":"2026-10-24T05:04:04.553Z","confidence":1,"stale":false},"section_routes":{"fact_id":"b034f94c-cfdb-4936-9649-594621fdf32c","source_url":"https://clinicaltrials.gov/api/int/studies?query.intr=retatrutide&filter.overallStatus=RECRUITING,NOT_YET_RECRUITING&limit=50&fields=NCTId,BriefTitle,OfficialTitle,OverallStatus,Phase,LeadSponsorName,Condition,InterventionName,LocationState,LocationCountry,BriefSummary,StartDate,LastUpdatePostDate","source_type":"primary","captured_at":"2026-10-24T04:40:13.483Z","checked_at":"2026-10-25T06:28:29.863Z","confidence":1,"stale":false},"regulatory_as_of":{"fact_id":"9ca4da6d-58da-4416-ad81-40ea108d8474","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","source_type":"primary","captured_at":"2026-10-24T04:24:23.450Z","checked_at":"2026-10-24T05:04:04.554Z","confidence":1,"stale":false},"section_channels":{"fact_id":"6702e765-c49d-4f58-b79f-2af8a853c8e3","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","source_type":"primary","captured_at":"2026-10-24T04:24:23.450Z","checked_at":"2026-10-24T05:04:04.560Z","confidence":1,"stale":false},"section_evidence":{"fact_id":"ce617e6c-1786-40f9-8995-e0ea468b2bf2","source_url":"https://pubmed.ncbi.nlm.nih.gov/42810372/","source_type":"peer-reviewed","captured_at":"2026-10-24T04:40:18.805Z","checked_at":"2026-10-24T05:04:04.562Z","confidence":1,"stale":false},"regulatory_status":{"fact_id":"f220bf37-ee5b-4711-86ae-e2eda6a820e0","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","source_type":"primary","captured_at":"2026-10-24T04:24:23.450Z","checked_at":"2026-10-24T05:04:04.556Z","confidence":1,"stale":false},"section_what_it_is":{"fact_id":"b893bcc6-b94b-4311-960c-702b1d6cf233","source_url":"https://pubmed.ncbi.nlm.nih.gov/37366315/","source_type":"peer-reviewed","captured_at":"2026-10-24T04:40:15.749Z","checked_at":"2026-10-24T05:04:04.567Z","confidence":1,"stale":false},"section_is_it_legal":{"fact_id":"d21733d5-13aa-43d9-bb42-90af34d75c31","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","source_type":"primary","captured_at":"2026-10-24T04:24:23.450Z","checked_at":"2026-10-24T05:04:04.564Z","confidence":1,"stale":false},"unofficial_channels":{"fact_id":"425f524f-5d0a-4d25-b28c-8491036dd9bb","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","source_type":"primary","captured_at":"2026-10-24T04:24:23.450Z","checked_at":"2026-10-26T00:00:27.207Z","confidence":1,"stale":false}},"citationsBySection":{"known_risks":[{"n":9,"title":"Phase 2 trial of retatrutide in adults with obesity, 2023","url":"https://pubmed.ncbi.nlm.nih.gov/37366315/"},{"n":10,"title":"Phase 2 trial of retatrutide in adults with type 2 diabetes, 2023","url":"https://pubmed.ncbi.nlm.nih.gov/37385280/"},{"n":13,"title":"TRIUMPH-2: phase 3 trial of retatrutide in obesity with type 2 diabetes, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42810372/"},{"n":16,"title":"CBS News: lab tests of products sold as retatrutide, October 2026","url":"https://www.cbsnews.com/news/tested-experimental-weight-loss-drug-results/"},{"n":5,"title":"FDA warning letter to an online seller of research-use retatrutide, 31 March 2026","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026"}],"open_questions":[{"n":13,"title":"TRIUMPH-2: phase 3 trial of retatrutide in obesity with type 2 diabetes, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42810372/"},{"n":12,"title":"TRANSCEND-T2D-1: phase 3 trial of retatrutide in type 2 diabetes, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42250575/"},{"n":11,"title":"Phase 2a trial of retatrutide for fatty liver disease, 2024","url":"https://pubmed.ncbi.nlm.nih.gov/38858523/"},{"n":7,"title":"ClinicalTrials.gov: recruiting and not yet recruiting studies of retatrutide","url":"https://clinicaltrials.gov/api/int/studies?query.intr=retatrutide&filter.overallStatus=RECRUITING,NOT_YET_RECRUITING&limit=50&fields=NCTId,BriefTitle,OfficialTitle,OverallStatus,Phase,LeadSponsorName,Condition,InterventionName,LocationState,LocationCountry,BriefSummary,StartDate,LastUpdatePostDate"},{"n":16,"title":"CBS News: lab tests of products sold as retatrutide, October 2026","url":"https://www.cbsnews.com/news/tested-experimental-weight-loss-drug-results/"},{"n":8,"title":"ArentFox Schiff: research-use labels are not a legal strategy, 18 September 2026","url":"https://www.afslaw.com/perspectives/alerts/ruo-ined-five-peptide-vendors-learn-research-use-only-not-legal-strategy"},{"n":15,"title":"CBS News: the maker sues sellers of its experimental weight-loss drug, August 2026","url":"https://www.cbsnews.com/news/eli-lilly-lawsuits-weight-loss-drug/"}],"section_routes":[{"n":1,"title":"FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},{"n":7,"title":"ClinicalTrials.gov: recruiting and not yet recruiting studies of retatrutide","url":"https://clinicaltrials.gov/api/int/studies?query.intr=retatrutide&filter.overallStatus=RECRUITING,NOT_YET_RECRUITING&limit=50&fields=NCTId,BriefTitle,OfficialTitle,OverallStatus,Phase,LeadSponsorName,Condition,InterventionName,LocationState,LocationCountry,BriefSummary,StartDate,LastUpdatePostDate"},{"n":3,"title":"FDA warning letter on compounded retatrutide, 9 September 2025","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genlabmeds-713650-09092025"}],"section_channels":[{"n":1,"title":"FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},{"n":2,"title":"FDA warning letter to an online seller of research-use peptides, 10 December 2024","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-vitality-inc-dba-prime-peptides-695156-12102024"},{"n":5,"title":"FDA warning letter to an online seller of research-use retatrutide, 31 March 2026","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026"},{"n":6,"title":"FDA warning letter to an online seller of research-use peptides, 24 August 2026","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026"},{"n":16,"title":"CBS News: lab tests of products sold as retatrutide, October 2026","url":"https://www.cbsnews.com/news/tested-experimental-weight-loss-drug-results/"},{"n":3,"title":"FDA warning letter on compounded retatrutide, 9 September 2025","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genlabmeds-713650-09092025"},{"n":4,"title":"FDA warning letter on compounded retatrutide, 9 September 2025, second business","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medclub-dr-jenn-712126-09092025"},{"n":15,"title":"CBS News: the maker sues sellers of its experimental weight-loss drug, August 2026","url":"https://www.cbsnews.com/news/eli-lilly-lawsuits-weight-loss-drug/"},{"n":8,"title":"ArentFox Schiff: research-use labels are not a legal strategy, 18 September 2026","url":"https://www.afslaw.com/perspectives/alerts/ruo-ined-five-peptide-vendors-learn-research-use-only-not-legal-strategy"}],"section_evidence":[{"n":9,"title":"Phase 2 trial of retatrutide in adults with obesity, 2023","url":"https://pubmed.ncbi.nlm.nih.gov/37366315/"},{"n":12,"title":"TRANSCEND-T2D-1: phase 3 trial of retatrutide in type 2 diabetes, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42250575/"},{"n":13,"title":"TRIUMPH-2: phase 3 trial of retatrutide in obesity with type 2 diabetes, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42810372/"},{"n":10,"title":"Phase 2 trial of retatrutide in adults with type 2 diabetes, 2023","url":"https://pubmed.ncbi.nlm.nih.gov/37385280/"},{"n":11,"title":"Phase 2a trial of retatrutide for fatty liver disease, 2024","url":"https://pubmed.ncbi.nlm.nih.gov/38858523/"},{"n":14,"title":"Review of trials of retatrutide for obesity, 2025","url":"https://pubmed.ncbi.nlm.nih.gov/39817343/"},{"n":16,"title":"CBS News: lab tests of products sold as retatrutide, October 2026","url":"https://www.cbsnews.com/news/tested-experimental-weight-loss-drug-results/"}],"section_what_it_is":[{"n":9,"title":"Phase 2 trial of retatrutide in adults with obesity, 2023","url":"https://pubmed.ncbi.nlm.nih.gov/37366315/"},{"n":10,"title":"Phase 2 trial of retatrutide in adults with type 2 diabetes, 2023","url":"https://pubmed.ncbi.nlm.nih.gov/37385280/"},{"n":16,"title":"CBS News: lab tests of products sold as retatrutide, October 2026","url":"https://www.cbsnews.com/news/tested-experimental-weight-loss-drug-results/"},{"n":12,"title":"TRANSCEND-T2D-1: phase 3 trial of retatrutide in type 2 diabetes, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42250575/"},{"n":13,"title":"TRIUMPH-2: phase 3 trial of retatrutide in obesity with type 2 diabetes, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42810372/"},{"n":1,"title":"FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"}],"section_is_it_legal":[{"n":1,"title":"FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},{"n":7,"title":"ClinicalTrials.gov: recruiting and not yet recruiting studies of retatrutide","url":"https://clinicaltrials.gov/api/int/studies?query.intr=retatrutide&filter.overallStatus=RECRUITING,NOT_YET_RECRUITING&limit=50&fields=NCTId,BriefTitle,OfficialTitle,OverallStatus,Phase,LeadSponsorName,Condition,InterventionName,LocationState,LocationCountry,BriefSummary,StartDate,LastUpdatePostDate"},{"n":13,"title":"TRIUMPH-2: phase 3 trial of retatrutide in obesity with type 2 diabetes, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42810372/"},{"n":16,"title":"CBS News: lab tests of products sold as retatrutide, October 2026","url":"https://www.cbsnews.com/news/tested-experimental-weight-loss-drug-results/"},{"n":3,"title":"FDA warning letter on compounded retatrutide, 9 September 2025","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genlabmeds-713650-09092025"},{"n":2,"title":"FDA warning letter to an online seller of research-use peptides, 10 December 2024","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-vitality-inc-dba-prime-peptides-695156-12102024"},{"n":5,"title":"FDA warning letter to an online seller of research-use retatrutide, 31 March 2026","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026"},{"n":6,"title":"FDA warning letter to an online seller of research-use peptides, 24 August 2026","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026"},{"n":8,"title":"ArentFox Schiff: research-use labels are not a legal strategy, 18 September 2026","url":"https://www.afslaw.com/perspectives/alerts/ruo-ined-five-peptide-vendors-learn-research-use-only-not-legal-strategy"},{"n":15,"title":"CBS News: the maker sues sellers of its experimental weight-loss drug, August 2026","url":"https://www.cbsnews.com/news/eli-lilly-lawsuits-weight-loss-drug/"}]},"channelsOpener":"This section describes what happens and is not a recommendation.","sources":["https://clinicaltrials.gov/api/int/studies?query.intr=retatrutide&filter.overallStatus=RECRUITING,NOT_YET_RECRUITING&limit=50&fields=NCTId,BriefTitle,OfficialTitle,OverallStatus,Phase,LeadSponsorName,Condition,InterventionName,LocationState,LocationCountry,BriefSummary,StartDate,LastUpdatePostDate","https://clinicaltrials.gov/api/v2/studies?query.intr=retatrutide+OR+LY3437943&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState","https://peptideindex.ai/methodology#evidence-grade","https://peptideindex.ai/methodology#short-answer","https://pubmed.ncbi.nlm.nih.gov/37366315/","https://pubmed.ncbi.nlm.nih.gov/42810372/","https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"],"verified_at":"2026-10-26T00:00:27.207Z","published_at":"2026-10-26T00:03:25.718Z","parent":null,"children":[],"snapshots":{"trials":{"snapshot_at":"2026-10-24T13:34:34.504Z","stale":false,"notice":"A listing is not a recommendation. Trials have strict eligibility rules. Talk to your doctor and read the official record."}}}